Cellosaurus cell line iOvCa250 (CVCL

Cellosaurus iOvCa250 (CVCL_VQ45)

[Text version]

Cell line name

iOvCa250

Accession

CVCL_VQ45

Resource Identification Initiative

To cite this cell line use: iOvCa250 (RRID:CVCL_VQ45)

Comments

Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.

Sequence variations

Mutation; HGNC; HGNC:583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Homozygous (PubMed=27822414).
Mutation; HGNC; HGNC:6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Heterozygous (PubMed=27822414).
Mutation; HGNC; HGNC:6342; KIT; Simple; p.Met541Leu (c.1621A>C); ClinVar=VCV000041599; Zygosity=Heterozygous (PubMed=27822414).

Disease

Low grade ovarian serous adenocarcinoma (NCIt: C105556)

Species of origin

Homo sapiens (Human) (NCBI Taxonomy: 9606)

Sex of cell

Female

Age at sampling

61Y

Category

Cancer cell line

STR profile

Source(s): PubMed=27822414

Markers:

Amelogenin	X
CSF1PO	11
D5S818	11,12
D7S820	9,12
D13S317	13,14
D16S539	9,12
D21S11	29,31.2
TH01	6,9.3
TPOX	11,12
vWA	16

Publications

DOI=10.14288/1.0319145
Dawson A.
Targeted therapy in low-grade serous ovarian carcinoma: characterization of MEK inhibitor response in novel patient-derived cell lines.
Thesis PhD (2016); University of British Columbia; Vancouver; Canada

PubMed=27822414; PMCID=PMC5088288
Fernandez M.L., DiMattia G.E., Dawson A., Bamford S., Anderson S., Hennessy B.T., Anglesio M.S., Shepherd T.G., Salamanca C.M., Hoenisch J., Tinker A., Huntsman D.G., Carey M.S.
Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.
Am. J. Cancer Res. 6:2235-2251(2016)

Cross-references

Cell line databases/resources

cancercelllines; CVCL_VQ45

Encyclopedic resources

Wikidata; Q94319947

Entry history

Entry creation

07-Sep-2018

Last entry update

19-Dec-2024

Version number